Filing Details
SAB Biotherapeutics, Inc. (NASDAQ:SABS) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 05, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:SABS
SAB Biotherapeutics, Inc. (SABS) Files Quarterly Report for Q0
SAB Biotherapeutics, Inc. (NASDAQ:SABS) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 05, 2026.
At publication ·
What changed
SAB Biotherapeutics, Inc. (NASDAQ:SABS) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- SAB Biotherapeutics filed its quarterly report (Form 10-Q) on November 5, 2026.
- The company's stock trades at $3.18 with a market capitalization of $34.3 million.
- The quarterly report includes unaudited financial statements and management commentary on business performance and conditions.
Market Context
SAB Biotherapeutics, Inc.'s stock currently trades at $3.18 with a market capitalization of $34.3M.
The 10-Q provides SAB Biotherapeutics, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for SAB Biotherapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View SABS Stock Page
Frequently Asked Questions
Where can I read SABS's SEC filings?
Browse all filings on our SABS SEC filings page.
What types of SEC filings does SAB Biotherapeutics, Inc. file?
Public companies like SAB Biotherapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.